title: Transcription of adenovirus and HeLa cell genes in the presence of drugs that inhibit topoisomerase I and II function.
abstract: The requirements for topoisomerases in transcription of adenovirus and HeLa cell genes were analyzed using drugs that specifically inhibit either topoisomerases I or II. Cleavage of viral DNA by topoisomerases in the presence of either camptothecin or VM26 was used to determine drug concentrations that led to maximal inhibition of ligation in the cleavage and ligation step of topoisomerase I or II respectively. Inhibition of topoisomerase II with VM26 did not cause a direct reduction in transcription of adenoviral genes or HeLa cell heat shock genes. VM26 did, however, interfere with other cellular processes. It reduced nucleoside uptake into HeLa cells from the medium, and it altered the normal nuclear to cytoplasmic ratio of specific RNAs. Treatment of cells with camptothecin to inhibit topoisomerase I reduced but did not abolish transcription of viral and HeLa cell genes. Transcription mediated by both RNA polymerases I and II was reduced. Topoisomerase II did not appear to substitute for topoisomerase I in transcription since treatment of cells with VM26 and camptothecin did not reduce transcript accumulation relative to cells treated with camptothecin alone.
authors.affiliation: Howard Hughes Medical Institute, Department of Biology, Princeton University, NJ 08544.
authors.forename: J
authors.initials: J
authors.lastname: Schaak
authors.forename: P
authors.initials: P
authors.lastname: Schedl
authors.forename: T
authors.initials: T
authors.lastname: Shenk
mesh_terms: D017456:Adenovirus Early Proteins; D000260:Adenoviruses, Human / Q000235:genetics*; D000957:Antigens, Viral, Tumor / Q000235:genetics; D002166:Camptothecin / Q000494:pharmacology*; D005091:Exons; D005796:Genes / Q000187:drug effects; D005814:Genes, Viral / Q000187:drug effects; D006367:HeLa Cells / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D006360:Heat-Shock Proteins / Q000235:genetics; D006801:Humans; D007700:Kinetics; D009856:Oncogene Proteins, Viral / Q000235:genetics; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D012333:RNA, Messenger / Q000187:drug effects / Q000235:genetics; D013713:Teniposide / Q000494:pharmacology*; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors; D014158:Transcription, Genetic
chemical_list: D017456:Adenovirus Early Proteins; D000957:Antigens, Viral, Tumor; D006360:Heat-Shock Proteins; D009856:Oncogene Proteins, Viral; D012333:RNA, Messenger; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors; D013713:Teniposide; D011034:Podophyllotoxin; D002166:Camptothecin